New Zealand women with ovarian cancer finally have funded access to bevacizumab. Pharmac’s announcement yesterday comes ten years after the treatment was funded in Australia, and follows a long fight ...

Amezalpat has been granted FDA fast track designation as treatment for patients with hepatocellular carcinoma.

WOBURN, Mass., Feb. 12, 2025 (GLOBE NEWSWIRE) -- Replimune Group, Inc. (Nasdaq: REPL), a clinical stage biotechnology company pioneering the development of novel oncolytic immunotherapies, today ...

A dual-responsive hydrogel offers a breakthrough in osteoarthritis treatment by inhibiting neurovascularization and reducing ...

Amezalpat received fast track designation from the FDA for the treatment of patients with hepatocellular carcinoma.

The FDA has granted fast track designation to amezalpat for the treatment of patients with hepatocellular carcinoma.

Amezalpat is an investigational oral, small molecule, selective peroxisome proliferator-activated receptor-alpha antagonist.

Dr. Jennifer Kissner, SVP Clinical Development, discusses the 12-week safety and efficacy results for NORSE EIGHT clinical trialWatch the “What ...

Dr. Filippo Pietrantonio discusses OrigAMI-1 trial data which assessed Rybrevant in mutated, wild-type, non-HER2-amplified metastatic colorectal cancer.

Next: Access Our New, Shockingly Simple 'Alert System' The trial showed a statistically significant and clinically meaningful ...

A recent study revealed that bevacizumab (Avastin) provides survival benefits in patients with colorectal cancer (CRC) for ...